Tavilermide (MIM-D3) is a cyclic peptide and selective Tropomyosin receptor kinase A (TrkA) agonist. It is utilized in research models of dry eye disease, including in vitro assays for neurite outgrowth and in vivo studies for corneal epithelial healing and tear production.